HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Progressive endothelin-1 gene activation initiates chronic/end-stage renal disease following experimental ischemic/reperfusion injury.

Abstract
This study assessed whether endothelin-1 (ET-1) helps mediate postischemic acute kidney injury (AKI) progression to chronic kidney disease (CKD). The impact(s) of potent ETA or ETB receptor-specific antagonists (Atrasentan and BQ-788, respectively) on disease progression were assessed 24 h or 2 weeks following 30 min of unilateral ischemia in CD-1 mice. Unilateral ischemia caused progressive renal ET-1 protein/mRNA increases with concomitant ETA, but not ETB, mRNA elevations. Extensive histone remodeling consistent with gene activation and increased RNA polymerase II (Pol II) binding occurred at the ET-1 gene. Unilateral ischemia produced progressive renal injury as indicated by severe histologic injury and a 40% loss of renal mass. Pre- and post-ischemia or just postischemic treatment with Atrasentan conferred dramatic protective effects such as decreased tubule/microvascular injury, normalized tissue lactate, and total preservation of renal mass. Nuclear KI-67 staining was not increased by Atrasentan, implying that increased tubule proliferation was not involved. Conversely, ETB blockade had no protective effect. Thus, our findings provide the first evidence that ET-1 operating through ETA can have a critical role in ischemic AKI progression to CKD. Blockade of ETA provided dramatic protection, indicating the functional significance of these results.
AuthorsRichard A Zager, Ali C M Johnson, Dennis Andress, Kirsten Becker
JournalKidney international (Kidney Int) Vol. 84 Issue 4 Pg. 703-12 (Oct 2013) ISSN: 1523-1755 [Electronic] United States
PMID23698233 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Endothelin A Receptor Antagonists
  • Endothelin B Receptor Antagonists
  • Endothelin-1
  • Oligopeptides
  • Piperidines
  • Pyrrolidines
  • RNA, Messenger
  • Receptor, Endothelin A
  • Receptor, Endothelin B
  • BQ 788
  • Atrasentan
Topics
  • Animals
  • Atrasentan
  • Disease Models, Animal
  • Disease Progression
  • Endothelin A Receptor Antagonists
  • Endothelin B Receptor Antagonists
  • Endothelin-1 (genetics, physiology)
  • Kidney Failure, Chronic (etiology, physiopathology)
  • Male
  • Mice
  • Mice, Inbred Strains
  • Oligopeptides (pharmacology)
  • Piperidines (pharmacology)
  • Pyrrolidines (pharmacology)
  • RNA, Messenger (genetics)
  • Receptor, Endothelin A (drug effects, physiology)
  • Receptor, Endothelin B (drug effects, physiology)
  • Renal Insufficiency, Chronic (etiology, physiopathology)
  • Reperfusion Injury (complications, physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: